Clinical evaluation of recombinant human growth hormone in Noonan syndrome.

@article{Ogawa2004ClinicalEO,
  title={Clinical evaluation of recombinant human growth hormone in Noonan syndrome.},
  author={Masamichi Ogawa and Naoki Moriya and Hiroyuki Ikeda and Ayako Tanae and Toshiaki Tanaka and Kenji Ohyama and Osamu Mori and Takeshi Yazawa and Keinosuke Fujita and Yoshiki Seino and Toshihide Kubo and Hiroyuki Tanaka and Yoshikazu Nishi and Masaaki Yoshimoto},
  journal={Endocrine journal},
  year={2004},
  volume={51 1},
  pages={61-8}
}
The objective of this study was to investigate the effect of administration of recombinant human growth hormone (hGH) in patients with Noonan syndrome. hGH was administered (0.5 IU/kg/week) to 15 patients with Noonan syndrome over a 2 year period. Average patient age prior to therapy was 7.5 +/- 2.5 (mean +/- SD) yr, the height SD score was -2.8 +/- 0.7, and the pretreatment height velocity and bone age were 4.8 +/- 1.0 cm/yr and 5.8 +/- 2.1 yr, respectively. The height velocity in the year… CONTINUE READING